Expanding the Promise of Immunotherapy

Leveraging elite immune responses to develop novel cancer immunotherapies


The Right People in the Right Place at the Right Time

Making advancements in immuno-oncology through strategic partnerships



January 2, 2018
OncoResponse Expands Scientific Leadership with the Addition of Dr. Anil Singhal as CSO and Dr. Kamal D.. Puri as VP of R&D

November 7, 2017
OncoResponse Adds Anti-EMP2 Antibody to Oncology Pipeline Through Acquisition of Paganini Biopharma